Self-sampling of capillary blood for SARS-CoV-2 serology

Lottie Brown1, Rachel L. Byrne1, Alice Fraser1, Sophie I. Owen1, Ana I. Cubas-Atienzar1, Christopher T. Williams1, Grant A. Kay1, Luis E. Cuevas1, Joseph R. A. Fitchett1, Tom Fletcher1, Gala Garrod1, Konstantina Kontogianni1, Sanjeev Krishna4, Stefanie Menzies1, Tim Planche1, Chris Sainter1, Henry M. Staines4, Lance Turtle3,5 & Emily R. Adams1*

Serological testing is emerging as a powerful tool to progress our understanding of COVID-19 exposure, transmission and immune response. Large-scale testing is limited by the need for in-person blood collection by staff trained in venepuncture, and the limited sensitivity of lateral flow tests. Capillary blood self-sampling and postage to laboratories for analysis could provide a reliable alternative. Two-hundred and nine matched venous and capillary blood samples were obtained from thirty nine participants and analysed using a COVID-19 IgG ELISA to detect antibodies against SARS-CoV-2. Thirty eight out of thirty nine participants were able to self-collect an adequate sample of capillary blood (≥ 50 µl). Using plasma from venous blood collected in lithium heparin as the reference standard, matched capillary blood samples, collected in lithium heparin-treated tubes and on filter paper as dried blood spots, achieved a Cohen’s kappa coefficient of > 0.88 (near-perfect agreement, 95% CI 0.738–1.000). Storage of capillary blood at room temperature for up to 7 days post sampling did not affect concordance. Our results indicate that capillary blood self-sampling is a reliable and feasible alternative to venepuncture for serological assessment in COVID-19.

Serological testing is emerging as a powerful tool to progress our understanding of SARS-CoV-2 transmission. Serological tests are able to detect specific antibodies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. In individuals who have been infected with the virus, immunoglobulin G (IgG) antibodies specific to viral proteins appear approximately 6–15 days after infection1. The longevity of this antibody response and whether it confers neutralising or protective immunity is still uncertain, but evidence suggests IgG antibodies may be detected for months following infection2–7. Wide-scale serological testing is key to improving our understanding of longitudinal antibody responses and immunity in COVID-19 and for epidemiological analyses.

Many of the currently available antibody tests for SARS-CoV-2, such as those that use enzyme-linked immunosorbent assay (ELISA) technology, require serum or plasma collected by venepuncture. Collection of venous blood is labour and resource-intensive, as it demands trained healthcare staff, facilities, personal protective equipment (PPE), and that the participant must attend a health facility in person for collection. Bringing individuals into the healthcare environment for sampling increases the risk of COVID-19 transmission8, 9. On a large-scale, this type of sampling is impractical, particularly in low and middle-income countries (LMICs), where resources and healthcare personnel are limited.

An alternative is surveillance of antibody response by rapid lateral flow immunoassays (LFIA). However, the performance of the first generation of assays is variable, even when conducted by trained staff in a clinical setting10. A U.K. seroprevalence study evaluated finger prick self-testing by LFIA at home and found highly variable sensitivity (21% to 92%), that was significantly inferior to ELISAs performed on venous blood11. Studies have shown high sensitivity of ELISAs for the detection of SARS-CoV-2 antibodies in venous blood4, 12, 13. Capillary blood is a well-established specimen in ELISA diagnostics but it is yet to be evaluated in SARS-CoV-2 infection. If individuals were able to self-sample blood in their own home and post dried blood spots to a reference laboratory...
or house to house collection, this would mitigate the potential transmission risks for inpatient sampling, boost community surveillance and open sampling to a wider population; yet retain the use of sensitive ELISA assays. The aims of this study were to determine the feasibility of capillary blood self-sampling and to compare the COVID-19 IgG ELISA results from samples derived from capillary blood with those from blood samples obtained by venepuncture. We investigated the stability of SARS-CoV-2 antibodies in capillary blood stored at room temperature over 7 days. Additionally, we determined whether the performance of COVID-19 IgG ELISA was equivalent on capillary blood collected on dried blood spots (DBS).

**Methods**

**Study participants.** Individuals were recruited based on past positive SARS-CoV-2 PCR result (n = 7), positive antibody test (n = 10) or both (n = 1), all participants were classified with mild symptoms of COVID-19 and none presented or were admitted to hospital. Healthy volunteers who had not experienced symptoms of COVID-19 were enrolled as negative controls. Participants were recruited on an existing study (the Human Immune Responses to Acute Viral Infections study, 16/NW/0160), after ethical approval was sought for repurposing the study for COVID-19. All experimental protocols were approved by the Liverpool School of Tropical Medicine Research Ethics Committee. All procedures were conducted in accordance with the relevant guidelines and regulations. All participants gave informed consent for the use of their samples in this study. A total of 18 participants were classified as serologically positive and 21 as serologically negative based on the results of COVID-19 IgG ELISA performed plasma from venous blood collected in lithium heparin tubes, which was taken as a reference.

**Venous blood collection.** Healthcare staff trained in venepuncture collected four tubes (approximately 20 ml) of venous blood per participant. Blood collection tubes (BD Vacutainer, UK); one treated with lithium heparin, one with potassium ethylenediaminetetraacetic acid (EDTA) and one with sodium citrate were used for plasma separation. A final tube, treated with silica additive, was used for serum separation. Blood was processed following the manufacturer's instructions according to tube type.

**Capillary blood collection.** Capillary blood was collected using Microvette 100 capillary tubes by Sarstedt (Sarstedt Nümbrecht, Germany), which are treated with lithium heparin. The self-sampling procedure was explained to each participant by the investigator. Participants were advised to place their non-dominant hand in a warm water for 1–3 min, before thoroughly drying with clean paper towels. Participants then cleaned the ring finger with an alcohol wipe and punctured with a 2.8 mm SurgiLance lancet (Medipurpose, New Malden, Surrey, UK). Blood flow was encouraged by massaging the finger in the direction of the puncture site until a large droplet of blood formed. The participant then brought the capillary tube in contact with the blood to draw it into the tube and continue this process until approximately 50 µl of blood had been collected. An additional four capillary samples of ≥ 50 µl each were taken by the study investigators, dependent upon sufficient blood flow and absence of clotting. A maximum of four puncture sites, each on separate fingers, were used for collection. The volume of self-collected capillary blood was recorded.

**Sample storage and processing.** The first self-collected capillary sample was designated "day 1 refrigerated", and immediately stored at 2–8 °C along with venous plasma and serum. The remaining capillary blood samples were stored at room temperature (21–25 °C) for testing at days 1, 3, 5 and 7. Immediately before testing, capillary blood samples were centrifuged for 5 min at 10,000 × g and 25 °C to obtain plasma.

**Detection of SARS-CoV-2 antibodies in capillary and venous blood.** On the day following sample collection (day 1), the venous and capillary samples (refrigerated and stored at room temperate) were run in triplicate on the COVID-19 IgG ELISA (Omega Diagnostics Ltd, Littleport, Cambridgeshire, UK) according to manufacturer's instructions; positive, cut-off, and negative controls were run in duplicate. Samples with a mean OD value of 10% greater than the cut-off control, as defined in the manufacturer's instructions, were regarded as positive for SARS-CoV-2 antibodies. Participants were deemed positive or negative based on their day 1 venous plasma (lithium heparin) IgG result. On day 1, 3, 5 and 7, plasma was obtained from stored capillary blood samples (room temperature) and run in triplicate on the COVID-19 IgG ELISA. If fewer than five capillary samples had been obtained, priority was given to testing on day 5, day 1, day 3 and then day 7.

**Dried blood spot (DBS).** To determine whether comparable results were achieved using capillary blood deposited on dried blood spots (DBS), 50 µl of capillary blood stored in lithium-heparin treated tubes at room temperature for 5 days was mixed by vortex, pipetted onto 903 Whatman card and left to dry (Cytiva, Malborough, USA). After one hour, a single 6 mm disc was punched out and eluted in 1000 µl of COVID-19 IgG ELISA diluent and incubated at 2–8 °C for 16 h. The eluate was then treated as a diluted sample and run in triplicate in the ELISA.

**Statistical analysis.** The mean absorbance (OD450nm) values for each sample and control were tabulated. Agreement of COVID-19 IgG ELISA results on different blood samples was assessed by determining the Cohen's kappa coefficient with 95% confidence intervals (95% CI). Cohen's Kappa coefficient is a statistical measure of the degree of agreement or concordance between two independent tests that takes into account the possibility that agreement could occur by chance alone. Raw OD values were normalised to allow comparison across ELISA plates. For each plate the mean cut-off OD value plus 10% was subtracted from each mean sample OD
value. The resulting value was divided by the mean positive control OD value to give a normalised OD. Statistical analyses were performed using Prism (version 8, GraphPad, USA). Correlations between OD values were assessed using Spearman’s rank test and a p value < 0.05 was considered statistically significant. Agreement in normalised OD results across sample types was measured by Bland–Altman mean difference.

**Ethics.** The participants in this study were recruited onto the Human Immune responses to Acute Virus Infections study, which was reviewed and approved by the National Health Service Research Ethics Committee Liverpool Central, IRAS number 16/NW/0160.

**Results**

**Participant characteristics.** A total of 39 participants were included, of which 22 (56.4%) were female (Table 1). The median age was 37 years (range = 23–64 years). Only one participant was not able to self-collect an adequate capillary blood sample ≥ 50 µl.

**Agreement between COVID-19 IgG ELISA results, using capillary and venous blood samples.** Here, we report high agreement between capillary and venous blood samples for the detection of SARS-CoV-2 antibodies by IgG ELISA. As shown in Table 2, agreement of the samples was consistently high (≥ 94%) and storage at room temperature for 7 days did not affect concordance. Discordance occurred between only five of 209 matched venous and capillary samples (2.4%), giving Cohen’s kappa coefficient > 0.88 for all sample types (near-perfect agreement, 95% CI 0.738–1.000). The cases of disagreement only occurred in samples from two patients (5.3%), with OD values close to the cut-off, when the reference venous blood was positive and capillary blood was indeterminate.

The OD detected by ELISA for 95 matched venous and capillary blood samples positive for SARS-CoV-2 antibodies were standardised and plotted. We found a strong correlation between the matched OD values of the positive samples (r = 0.65, 95% CI 0.51–0.76, p < 0.0001, Fig. 1) and minimal differences in results across all sample types, including capillary blood which was self-sampled (Bland–Altman Bias -0.05 ± 0.32).

This figure displays the relationship between the standardised OD values of venous plasma (collected in lithium heparin treated tubes) and of capillary blood samples (collected on all days in lithium heparin-treated tubes and deposited onto DBS) positive for SARS-CoV-2 antibodies. The black line indicates the linear regression result and shaded area is 95% confidence interval.

| Table 1. | Participant demographics. Data is N (%) or median (range). |
| --- | --- |
| **SARS-CoV-2 IgG positive** | **Negative controls** | **Total** |
| Number of participants | 18 (46.2%) | 21 (53.8%) | 39 (100%) |
| Sex |  |  |  |
| Female | 10 (55.6%) | 12 (57.1%) | 22 (56.4%) |
| Male | 8 (44.4%) | 9 (42.9%) | 17 (43.6%) |
| Median age (range) | 37 years (23–64 years) | 37 years (24–63 years) | 37 years (23–64 years) |
| Median time since symptom onset (range) | 105 days (20–125 days) | – | – |
| Able to self-collect capillary blood sample/50 µl | 17 (94.4%) | 21 (100%) | 38 (97.4%) |

| Table 2. | Agreement between results of the COVID-19 IgG ELISA performed on different sample types and days post sampling, compared with a reference standard of plasma from venous blood collected in lithium heparin-treated tubes. |
| --- | --- |
| **N** | **Agreement with standard** | **Cohen’s Kappa coefficient** | **95% CI** |
| Serum | 37 | 100% | 1.000 | – |
| EDTA | 37 | 97.3% | 0.946 | 0.841–1.000 |
| Sodium citrate | 37 | 97.3% | 0.946 | 0.841–1.000 |
| Day 1 refrigerated (self-collected n = 38) | 39 | 94.9% | 0.896 | 0.756–1.000 |
| Day 1 room temperature | 36 | 94.4% | 0.888 | 0.738–1.000 |
| Day 3 room temperature | 31 | 100% | 1.000 | – |
| Day 5 room temperature | 36 | 100% | 1.000 | – |
| Day 7 room temperature | 34 | 100% | 1.000 | – |
| Dried blood spots (DBS) | 33 | 97.0% | 0.939 | 0.820–1.000 |
Here, we report that results from a COVID-19 IgG ELISA performed on samples derived from capillary blood samples, which can be self-collected, are comparable to blood taken by venepuncture for the detection of SARS-CoV-2-specific antibodies. One of the bottlenecks to antibody testing in the COVID-19 pandemic, is the need for in-person venous blood collection by healthcare staff. The utilisation of an easy to self-collect specimen such as capillary blood offers improved access to serological testing. Almost all participants in our study (97.4%) were able to self-collect an adequate capillary blood sample for the Omega SARS-CoV-2 assay, which indicates self-sampling is a feasible alternative to venepuncture. In addition, we show SARS-CoV-2 antibodies within capillary blood are stable for up to one week (the limit of testing) at room temperature (21–25 °C). This mitigates the need for cold chain transportation and reduces the pressure on the postal service and laboratory staff for immediate testing. Cohen’s Kappa appeared to increase for samples stored at room temperature for up to 7 days, but this was likely biased by the smaller number of collected samples.

We report a high level of agreement between venous and capillary blood samples with only 2.4% of discordant samples across the study from two patients (5.3%). Furthermore, we found that the OD values of matched venous plasma and capillary samples were similar. Type of capillary blood (in lithium heparin-treated capillary tubes or deposited onto filter paper as DBS) did not affect equivalency. Capillary blood stored in lithium heparin-treated tubes can be processed immediately on receipt of samples. There are more manual pre-analytical steps when processing DBS samples, as they must be punched out and eluted before ELISA which can be time-consuming. An advantage of DBS samples over capillary blood tubes is the minimal biohazard risk during transport. Unlike liquid blood samples, DBS do not require special handling during postage or transport. Antibodies are known to remain stable in DBS for weeks at room temperature, although this has not yet been validated in antibodies against SARS-CoV-2.

There was disagreement between the results of venous and capillary blood sampling in 5 (2.4%) of samples from 2 participants (5.3%) in our study. Sensitivity in this non-severe group of participants was lower than has been reported for hospitalised severe patients, and seems likely that a lower antibody response is expected in non-severe patients. In every case of disagreement, the venous sample was low level positive, and the capillary sample was indeterminate. Therefore, if the results of the test are of particular importance to an individual, an indeterminate test could be repeated with a venous blood sample. As only 5 (2.4%) capillary samples gave indeterminate results, this still has the potential to reduce the amount of sampling necessary greatly.

Three studies have evaluated the use of DBS in comparison to venous blood samples for SARS-CoV-2 serology and found high concordance15–17. In this study, the method of collection presented little difficulty for our volunteers, with only one person not able to collect an adequate sample. However, more research exploring capillary blood collection preferences and acceptability in target populations is needed.

We plan to validate this method in future studies of large patient cohorts having contributed this proof of concept and completed the pilot. Both methods of capillary blood sampling are simple and inexpensive and are suited to LMICs, particularly where there is a lack of trained healthcare staff or geographically dispersed populations. Our findings indicate antibodies for SARS-CoV-2 are stable in capillary blood stored at 21–25 °C.

Figure 1. Linear relationship between standardised OD values of matched venous plasma collected in lithium heparin treated tubes and all capillary samples positive for SARS-CoV-2 antibodies.

\[
\text{Standardised capillary sample OD}
\]

\[
\begin{align*}
\text{Standardised reference sample OD} \\
P^2 = 0.6139 \\
p < 0.0001
\end{align*}
\]
However, to confirm the suitability of this method for tropical LMICs, we will repeat our study after storing capillary blood samples (collected in capillary tubes and as DBS) at a higher temperature.

The use of antibody testing in COVID-19 is limited by the risk of false negatives especially in non-severe and non-hospitalised patients. A number of recently published papers demonstrate transient antibody positivity among individuals previously infected with SARS-CoV-2 and in some cases, no antibody positivity.\textsuperscript{3,19}

Our results show that capillary blood self-sampling is a reliable and feasible alternative to venepuncture for serological assessment in COVID-19. This method will be particularly useful in large-scale disease surveillance and longitudinal research of immune response in COVID-19.

Received: 27 August 2020; Accepted: 18 January 2021
Published online: 08 April 2021

References
1. Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. \textit{Clin. Infect. Dis.} \url{https://doi.org/10.1093/cid/ciaa344} (2020).
2. Seikine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. \textit{bioRxiv} (2020). \url{https://doi.org/10.1101/2020.06.29.174888}.
3. Wajnberg, A. et al. Title: SARS-CoV-2 infection induces robust, neutralizing antibody responses that are 1 stable for at least three months 2, 3. \textit{medRxiv} (2020). \url{https://doi.org/10.1101/2020.07.14.20151126}.
4. Staines, H. M. et al. Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections. \textit{medRxiv} (2020). \url{https://doi.org/10.1101/2020.06.07.20124636}.
5. Reiter, J., Hayum, N., Heskel, B., Klagebald, I. & Streva, V. A. SARS-CoV-2 IgG Antibody Responses in New York City. \textit{medRxiv} 2020.05.23.20111427 (2020). \url{https://doi.org/10.1101/2020.05.23.20111427}.
6. Wu, J. et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 Correspondence. \textit{medRxiv} (2020). \url{https://doi.org/10.1101/2020.07.21.20159178}.
7. Liu, A., Li, Y., Peng, J., Huang, Y. & Xu, D. Antibody responses against SARS-CoV-2 in COVID-19 patients. \textit{J. Med. Virol.} \url{https://doi.org/10.1002/jmv.26241} (2020).
8. Sikkema, R. S. et al. COVID-19 in health-care workers in three hospitals in the south of the Netherlands: A cross-sectional study. \textit{Lancet Infect. Dis.} \url{https://doi.org/10.1016/S1473-3099(20)30527-2} (2020).
9. Wong, S. C. Y. et al. Risk of nosocomial transmission of coronavirus disease 2019: An experience in a general ward setting in Hong Kong. \textit{J. Hosp. Infect.} \textbf{105}(2), 119–127 (2020).
10. Whitman, J. D. et al. Test performance evaluation of SARS-CoV-2 serological assays. \textit{medRxiv} (2020). \url{https://doi.org/10.1101/2020.04.25.20074856}.
11. Flower, B. et al. Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. \textit{Thorax} \url{https://doi.org/10.1136/thoraxjnl-2020-215732} (2020).
12. Lisboa Bastos, M. et al. Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis. \textit{BMJ} \url{https://doi.org/10.1136/bmj.m2516} (2020).
13. Adams, E. R. et al. Rapid development of COVID-19 rapid diagnostics for low resource settings: Accelerating delivery through transparency, responsiveness, and open collaboration. \textit{medRxiv} (2020). \url{https://doi.org/10.1101/2020.04.29.20082099}.
14. Salem, J. A. Sources: Encyclopedia of research design. \textit{Ref. User Serv. Q.} \url{https://doi.org/10.5860/rusq.50n4.399} (2011).
15. McDade, T. W. et al. High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay. \textit{medRxiv} (2020). \url{https://doi.org/10.1101/2020.06.06.20119602}.
16. Morley, G. L. et al. Sensitive detection of SARS-CoV-2-specific antibodies in dried blood spot samples. \textit{medRxiv} (2020). \url{https://doi.org/10.1101/2020.07.01.20144295}.
17. Karp, D. G., Dahn, K., Seftel, D., Robinson, P. & Tsai, C.-T. A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots. \textit{medRxiv Prepr. Serv. Heal. Sci.} (2020). \url{https://doi.org/10.1101/2020.05.29.20116604}.
18. Huang, A. et al. A systematic review of antibody mediated immunity to coronaviruses: Antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. \textit{medRxiv Prepr. Serv. Heal. Sci.} (2020). \url{https://doi.org/10.1101/2020.04.14.20065771}.
19. Weiss, S. H. & Wormser, G. P. COVID-19: Understanding the science of antibody testing and lessons from the HIV epidemic. \textit{Diagn. Microbiol. Infect. Dis.} \url{https://doi.org/10.1016/j.diagmicrobio.2020.115078} (2020).

Acknowledgements
We are grateful to all the volunteers who enrolled into our study, for dedicating time during the pandemic to be involved in research.

Author contributions
E.R.A., J.R.A.F., L.E.C. and C.S. conceived and designed the study. L.T., H.S., S.K. and T.P. obtained ethical approval. L.B., R.L.B., S.I.O., A.I.C.A., G.K., T.F., S.M., G.G. and K.K. collected clinical data and patient samples. L.B. and C.W. obtained the laboratory data. L.B., A.F., S.I.O., C.W. analysed the laboratory data. L.B. wrote the first draft of the manuscript. All authors reviewed and approved the final version of the manuscript for submission.

Funding
This study was supported by the DFID/Wellcome Trust Epidemic Preparedness coronavirus grant (220764/Z/20/Z). ERA, LEC, TF and LT are funded by the Centre of Excellence in Infectious Diseases Research (CEIDR), the Alder Hey Charity and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool (UoL) with support from Public Health England (PHE), in collaboration with Liverpool School of Tropical (LSTM) Medicine and the University of Oxford. ERA, LEC and TF are based at LSTM; LT is based at UoL. LT is supported by a Wellcome fellowship (grant number 205228/Z/16/Z). HMS is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St. George's University of London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England.
Competing interests
SK is a member of the Scientific Advisory Committee for the Foundation for Innovative New Diagnostics (FIND) a not for profit organisation that produces global guidance on affordable diagnostics. The views expressed here are personal opinions and do not represent the recommendations of FIND. All other authors declare they have no conflicts of interest.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-86008-5.

Correspondence and requests for materials should be addressed to E.R.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021